The Technical Analyst
Aziyo Biologics, Inc. [AZYO]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Aziyo Biologics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.05% $1.490
America/New_York / 6 sep 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 24.21 mill |
| EPS: | -2.18 |
| P/E: | -0.683 |
| Earnings Date: | Nov 12, 2023 |
| SharesOutstanding: | 16.25 mill |
| Avg Daily Volume: | 0.433 mill |
| RATING 2023-10-03 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.683 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.683 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.208 - 1.572 ( +/- 13.09%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-28 | Highcape Capital, Llc | Sell | 1 436 077 | Class A Common Stock |
| 2023-12-28 | Highcape Capital, Llc | Sell | 2 154 116 | Warrants (right to buy) |
| 2023-12-28 | Highcape Capital, L.p. | Sell | 1 436 077 | Class A Common Stock |
| 2023-12-28 | Highcape Capital, L.p. | Sell | 2 154 116 | Warrants (right to buy) |
| 2021-09-21 | Highcape Capital, Llc | Buy | 2 837 128 | Class A Common Stock |
| INSIDER POWER |
|---|
| -79.75 |
| Last 95 transactions |
| Buy: 17 583 923 | Sell: 9 483 030 |
Forecast:
01:40 - $1.299
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.490 (2.05% ) |
| Volume | 0.0081 mill |
| Avg. Vol. | 0.433 mill |
| % of Avg. Vol | 1.873 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AZYO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AZYO
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Last 10 Buy Signals
Latest Press Releases
2023-09-08 08:30:00 - Press Release
Elutia To Present At The H.c. Wainwright 25th Annual Global Investment Conference
Silver spring, md., sept. 08, 2023 (globe newswire) -- elutia inc. (nasdaq: elut) (“elutia”), a company pioneering drug-eluting biomatrix products, today announced that dr. randy mills, president and chief executive officer, will present at the h.c. wainwright 25th annual global investment conference. the presentation will take place in new york on wednesday, september 13, 2023, at 2:30 pm et.
2023-08-30 08:30:00 - Press Release
Aziyo Biologics Announces Publication Of A Cangaroo® Case Study Demonstrating Bioenvelope Benefits For Reoperative Procedures
Case provides first histologic evidence that cangaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (cied) pocket
2023-08-14 16:05:00 - Press Release
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues To Drug-eluting Biomatrix Company
Negotiating multiple lois to divest orthopedic business cangaroo® rm 510(k) resubmission to the fda remains on track simpliderm® quarterly net sales up 32% year-over-year successful transfer of cardiovascular product distribution to lemaitre vascular silver spring, md., aug. 14, 2023 (globe newswire) -- aziyo biologics, inc. (nasdaq: azyo) (“aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended june 30, 2023.
2023-07-31 16:05:00 - Press Release
Aziyo Biologics To Report Second Quarter 2023 Financial Results On Monday, August 14, 2023
Silver spring, md., july 31, 2023 (globe newswire) -- aziyo biologics, inc. (nasdaq: azyo) (“aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on monday, august 14, 2023. members of the company's management team will host a conference call and webcast starting at 4:30 p.m. eastern time / 1:30 p.m. pacific time on the same day.
2023-07-13 16:30:00 - Press Release
Aziyo Biologics Announces Voluntary Recall Of Viable Bone Matrix Products
Silver spring, md., july 13, 2023 (globe newswire) -- aziyo biologics, inc. (nasdaq: azyo), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic and spinal procedures.
Latest News
2023-09-08 08:30:00 - GlobeNewsWire
Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will take place in New York on Wednesday, September 13, 2023, at 2:30 pm ET.
2023-08-20 12:41:05 - Seeking Alpha
Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matt Steinberg - FINN Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics' Second Quarter 2023 Financial Results Conference Call.
2023-07-31 16:05:00 - GlobeNewsWire
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
SILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
2023-05-14 21:32:09 - Seeking Alpha
Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics First Quarter 2023 Financial Results Conference Call.
2023-05-03 16:05:00 - GlobeNewsWire
Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
2023-04-05 11:26:30 - Zacks Investment Research
Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Aziyo Biologics, Inc. (AZYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-03-22 18:12:04 - Seeking Alpha
Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript
Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Aziyo Biologics Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.
2023-03-20 13:46:12 - Zacks Investment Research
ACER's Stock Down on Failure of Phase II Study, Cash Updates
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
2023-03-15 16:05:00 - GlobeNewsWire
Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023
SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
2023-02-27 08:15:00 - GlobeNewsWire
Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference
SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on Monday, March 6, 2023, at 9:50 am ET.